{"title":"Corrigendum to: Untangling Breast Cancer: Trailing Towards Nanoformulations-based Drug Development.","authors":"Ravinder Verma, Kuldeep Kumar, Shailendra Bhatt, Manish Yadav, Manish Kumar, Priti Tagde, P S Rajinikanth, Abhishek Tiwari, Varsha Tiwari, Diksha Nagpal, Vineet Mittal, Deepak Kaushik","doi":"10.2174/1872210521999261112114106","DOIUrl":"https://doi.org/10.2174/1872210521999261112114106","url":null,"abstract":"<p><p>Following publication of the article entitled \"Untangling Breast Cancer: Trailing Towards Nanoformulations-based Drug Development\" [1], certain phrases and expressions were identified that were unclear or inconsistent with established scientific terminology. To ensure accuracy and clarity of the published record, these expressions have been corrected using appropriate terminology that more accurately conveys the intended scientific meaning. These corrections are limited to the wording and terminology of the affected passages and do not alter the data, results, scientific interpretations, or conclusions of the article. The specific corrections are provided below: Section: 1.2.1.3. Metastatic BC, Paragraph: 1 Original text: Patients identified with metastatic illness (or de novo metastatic BC) at the outset of treatment may progress metastases months or years later. Unluckily, approximately 30% of females diagnosed with early-stage BC will go on to develop metastatic illness [22]. Corrected text: Patients identified with metastatic cancer (or de novo metastatic BC) at the outset of treatment may progress metastases months or years later. Unluckily, approximately 30% of females diagnosed with early-stage BC will go on to develop metastatic cancer [22]. Section: 3.3. Micelles: A Miracle Ball in BC Therapy, Paragraph: 1 Original text: These are solitary layer amphiphilic self-assembly networks, made by recapping entities of surfactant atoms [50]. Corrected text: These are single-layer amphiphilic self-assembly networks, made by recapping entities of surfactant atoms [50]. Section: 6. ROLE OF ARTIFICIAL INTELLIGENCE, Paragraph: 5 Original text: Du et al., (2022) create an artificial intelligence application that uses ultrasound (US) images to diagnose breast illness. To classify breast suspicious lesions as benign, malignant, or normal, a deep learning algorithm called Efficient-Det was created [119]. Breast cancer diagnosis utilizing breast ultrasound pictures was proposed by Qi et al., deep neural networks [120] were used in this manner. Corrected text: Du et al., (2022) create an artificial intelligence application that uses ultrasound (US) images to diagnose breast cancer. To classify breast suspicious lesions as benign, malignant, or normal, a deep learning algorithm called Efficient-Det was created [119]. Qi et al developed deep neural frameworks that can automatically diagnose breast cancer with help of ultrasonic images of breast [120] . The original article has been updated accordingly. This Corrigendum is published to ensure transparency and accuracy of the scholarly record. The corrected version of the article is available online at: https://www.eurekaselect.com/article/133241 The authors regret these errors and apologise for any inconvenience they may have caused.</p>","PeriodicalId":49324,"journal":{"name":"Recent Patents on Nanotechnology","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149412371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Vikas Singh, Rakhi Mishra, Rupa Mazumder, Avijit Mazumder, Anjna Rani
{"title":"Emerging Nanoparticle Therapeutic Approaches for Alzheimer's Disease: Target Sites and Mechanistic Insights.","authors":"Vikas Singh, Rakhi Mishra, Rupa Mazumder, Avijit Mazumder, Anjna Rani","doi":"10.2174/0118722105513615261105103058","DOIUrl":"https://doi.org/10.2174/0118722105513615261105103058","url":null,"abstract":"<p><strong>Introduction: </strong>Alzheimer's Disease (AD) is a progressive neurodegenerative condition and the most frequent cause of dementia among the elderly. AD is characterized by extracellular accumulation of amyloid plaques, neurofibrillary tangles, and glial responses, which result in neuronal and synaptic loss. The ongoing research into therapeutic interventions has shifted from symptomatic management toward disease-modifying strategies, including approaches targeting amyloid aggregation, tau pathology, neuroinflammation, and synaptic repair.</p><p><strong>Methods: </strong>The manuscript presents a thorough analysis of the targeted strategy, with particular emphasis on the application of nanoparticle-based systems for improve the management of Alzheimer's disease. Studies examining the role of tau protein, Amyloid Beta (Aβ), and other peptides in forming the pathological framework of Alzheimer's disease were included in the analysis.</p><p><strong>Results: </strong>Recent findings indicate that nanoparticle-based approaches have enhanced therapeutic efficacy through targeted drug delivery, improved penetration across the blood-brain barrier, and attenuation of neuroinflammation, thereby offering promising benefits in the management of Alzheimer's disease. The growing interest in nanotechnology-based interventions for Alzheimer's disease is reflected in a substantial number of patented innovations, including liposomal formulations, cerium oxide nanoparticles, and natural nanoparticle-pharmaceutical compositions.</p><p><strong>Discussion: </strong>Nanoparticle-based therapeutics demonstrate multifaceted efficacy in addressing Alzheimer's disease pathology. By directly inhibiting the accumulation and expression of key pathogenic targets-such as amyloid-beta and hyperphosphorylated tau-while simultaneously modulating microglial activity and neuroinflammatory cascades, nanotechnology targets mechanisms that traditional therapies often fail to resolve.</p><p><strong>Conclusion: </strong>Moving beyond conventional symptom-focused care, nano-enabled delivery systems offer a scalable strategy to enhance drug efficacy and cross the blood-brain barrier. Future research should prioritize translating these preclinical nanotherapeutic platforms into standardized clinical applications.</p>","PeriodicalId":49324,"journal":{"name":"Recent Patents on Nanotechnology","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149412332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Nanotechnology-Enabled Inhalable Therapeutics for Pulmonary Tuberculosis (TB): Preclinical Advances and Translational Prospects.","authors":"Archana Sahu, Biswajit Dash, Rakhi Mishra, Samir Gaur, Kajal Chaudhary, Laxmi Choudhary, Arijit Chaudhuri, Shakshi Verma, Mohit Vashishtha, Binita Ghosh, Akashdeep Singh, Rahul Pal","doi":"10.2174/0118722105488488261026075956","DOIUrl":"https://doi.org/10.2174/0118722105488488261026075956","url":null,"abstract":"<p><strong>Introduction/objective: </strong>Pulmonary tuberculosis (TB) remains a major global health challenge owing to prolonged therapy, poor adherence, systemic toxicity, and multidrug- and extensively drug-resistant Mycobacterium tuberculosis (Mtb). This review evaluates recent advances in nanotechnology- enabled inhalable therapeutics for pulmonary TB, focusing on preclinical performance, clinical development, and patent activity.</p><p><strong>Methods: </strong>Literature published during 2022-2025 was reviewed using PubMed, Scopus, Web of Science, and ClinicalTrials.gov.in Qualitative and quantitative evidence was synthesized for inhalable liposomes, dry powder inhalers, polymeric nanoparticles, solid lipid nanoparticles, nanomicelles, metal-organic frameworks, and related systems, emphasizing aerodynamic performance, drug loading, macrophage targeting, pulmonary retention, pharmacokinetics, antimicrobial efficacy, and safety.</p><p><strong>Results: </strong>Inhalable nanocarriers typically have particle sizes ranging from 80 to 500 nm and mass median aerodynamic diameters ranging from 1 to 5 μm, which supports deep lung deposition. Encapsulation efficiencies of 70-90% have been reported for first- and second-line anti-TB drugs. These drugs have been shown to have 2-6 times higher concentrations in the lungs and are retained in the lungs for longer than conventional formulations. Preclinical studies have demonstrated enhanced targeting of macrophages, intracellular drug delivery, sustained release, and reduced systemic exposure.</p><p><strong>Discussion: </strong>Despite encouraging preclinical findings, clinical translation remains limited by manufacturing scalability, long-term pulmonary toxicity, formulation and aerosolization variability, regulatory requirements, and insufficient clinical evidence.</p><p><strong>Conclusion: </strong>Nanotechnology-enabled inhalable therapeutics offer a promising approach to treating TB in the lungs. However, well-designed clinical trials, standardised inhalation protocols, long-term safety evaluations, and regulatory harmonisation are needed to establish their clinical efficacy and translational applicability.</p>","PeriodicalId":49324,"journal":{"name":"Recent Patents on Nanotechnology","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149412333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Nanorobotic Analytical Systems in Pharmaceutical Sciences: Translational Advances, Patents and Next-Generation Sensing Platforms.","authors":"Pranav Dhiman, Ankit Sharma, Inder Kumar, Pravin Kumar, Amar Deep Ankalgi, Mahendra Singh Ashawat","doi":"10.2174/0118722105511004261011123713","DOIUrl":"https://doi.org/10.2174/0118722105511004261011123713","url":null,"abstract":"<p><strong>Introduction: </strong>The growing molecular complexity of pharmaceuticals and biological systems poses challenges for conventional analytical methods, especially in obtaining real-time, ultrasensitive, spatially resolved, and decentralized measurements. This review examines the emerging role of nanorobotic analytical systems in pharmaceutical analysis, with an emphasis on their sensing, propulsion, actuation, navigation, and feedback capabilities.</p><p><strong>Methods: </strong>Structured literature and patent literature analyses were carried out to assess nanorobotic analytical platforms, nanoscale sensing approaches, analytical methods, pharmaceutical applications, and technological advances. A specific focus on distinguishing between passive nanomaterials and nanorobotic systems, as well as patent landscape analysis, has been made.</p><p><strong>Results: </strong>The reviewed literature demonstrates advances in the areas of enzyme-driven nanomotors, magnetically controlled nanorobots, DNA-based nanorobotic systems, nanoscale biosensors, and stimuli-responsive analytical platforms. The integration of microfluidics, lab-on-a-chip technologies, and artificial intelligence has expanded the potential for automated molecular detection, real-time monitoring, high-throughput screening, and pharmaceutical analysis.</p><p><strong>Discussion: </strong>Nanorobotic analytical systems offer potential benefits through the integration of molecular recognition, controlled motion, sensing, actuation, and programmable responses within miniaturized platforms. However, many reported systems are considered nanomaterial-enabled sensors or nanomotors rather than fully autonomous analytical nanorobots. The major challenges include scalable fabrication, reproducibility, standardization, biosafety, regulatory acceptance, and validation.</p><p><strong>Conclusion: </strong>Nanorobotic analytical systems represent an emerging analytical approach with potential applications in pharmaceutical quality assessment, molecular analysis, drug monitoring, and automated screening. Further advances in intelligent control, microfluidics, sensing, and artificial intelligence may facilitate their transition toward more autonomous and clinically relevant analytical platforms.</p>","PeriodicalId":49324,"journal":{"name":"Recent Patents on Nanotechnology","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149326735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Microneedles and Nanotechnology: Exploring their Interrelationship in a Patent Review.","authors":"Isabella Morel Bordignon, Katia Cinara Tregnago Cunha, Patrícia Weimer, Letícia Scherer Koester","doi":"10.2174/0118722105482934260714073847","DOIUrl":"https://doi.org/10.2174/0118722105482934260714073847","url":null,"abstract":"<p><strong>Introduction: </strong>Microneedle systems are a promising category of devices used for various applications, such as drug delivery and diagnostics, offering benefits, including but not limited to, painless administration and improved patient experience and compliance. When combined with nanotechnology, these systems can offer improved therapeutic performance.</p><p><strong>Methods: </strong>This article analyzed the patent landscape related to technologies combining microneedles and nanotechnology. Patent documents were retrieved from the Espacenet database up to 2024. After applying predefined inclusion and exclusion criteria, 932 patents were selected from an initial set of 1,368 documents. The patents were categorized according to application field, publication year, country, origin of the invention (academic, industrial, independent, or other), type of nanotechnology used, and target substance.</p><p><strong>Results: </strong>The results revealed an increasing global patent activity related to the integration of microneedles and nanotechnology. The patents covered diverse therapeutic and preventive applications and demonstrated the incorporation of multiple nanosystems, microneedle formats, and bioactive compounds.</p><p><strong>Discussion: </strong>It is notable that this technological association has a multidisciplinary nature and is increasingly relevant to drug delivery innovation. The diversity of approaches reflects the potential of combining nanotechnology with microneedle systems to address different challenges in a wide number of health-related fields.</p><p><strong>Conclusion: </strong>Overall, the patent landscape indicates a growing global interest in microneedlenanotechnology integration. The findings may support technological assessment, research planning, and the identification of collaboration opportunities between academia and industry.</p>","PeriodicalId":49324,"journal":{"name":"Recent Patents on Nanotechnology","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148609324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Indentation in Materials Science: Advances in Theory, Instrumentation, and Multiscale Applications.","authors":"Jingchun Wang, Cong Li, Junhao Fu, Shoubin Zhang","doi":"10.2174/0118722105449321260708100344","DOIUrl":"https://doi.org/10.2174/0118722105449321260708100344","url":null,"abstract":"<p><strong>Introduction: </strong>This review systematically examines the advances in micro-nano indentation technology, an innovative method for cross-dimensional extraction of mechanical properties, which overcomes limitations of traditional testing techniques.</p><p><strong>Methods: </strong>The development of instrumentation and standardization is reviewed. Key theoretical models and analysis methods are discussed, including the Oliver-Pharr method, strain gradient plasticity, viscoelastic models, and the Laugier model for fracture toughness. Recent patent-related innovations in hardware, such as in-situ high-temperature/vacuum systems (e.g., CN112229752A, CN117129355A) and high-speed sampling technologies, are highlighted.</p><p><strong>Results: </strong>The indentation response across various material systems (metals, ceramics, biomaterials, composites, flexible electronics, 2D materials) is analyzed. Case studies demonstrate successful applications in industrial coating evaluation, revealing Hall-Petch relationship anomalies in nanocrystalline metals, and inspiring biomimetic material design.</p><p><strong>Discussion: </strong>Challenges like surface roughness effects and instrument response delay during highstrain- rate testing are addressed, alongside solutions involving surface pretreatment and novel noisereduction algorithms (e.g., patent CN202411212667.8).</p><p><strong>Conclusion: </strong>Nanoindentation technology shows strong interdisciplinary potential. Future development should focus on in-situ multimodal systems, machine learning integration, standardization, and extreme environment testing, facilitating its transition from a characterization tool to a design platform. Relevant patented technologies play a crucial role in this evolution.</p>","PeriodicalId":49324,"journal":{"name":"Recent Patents on Nanotechnology","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148609402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"A Patent Analysis in Nano Biosensors with Nanomaterials.","authors":"Dengyu Li, Wen Luo, Ying Wang, Yanqing Zhao, Shiwei Zhu, Junfeng Yu, Zhuyan Xi, Shengwei Yin","doi":"10.2174/0118722105397248250919080111","DOIUrl":"https://doi.org/10.2174/0118722105397248250919080111","url":null,"abstract":"<p><p>Over the past decades, biosensor technologies have experienced significant advances with the rapid development of novel nanomaterials and nanotechnologies. The analysis was performed using a patent dataset of nanobiosensors, including 2709 patent documents. The number of patents has been growing rapidly since 2000. Currently, China and the USA are the main contributors to the number of patents. Based on patent data, the most commonly used nanomaterials in biosensors are primarily metal-based, polymer-based, and carbon-based nanomaterials. Recently, the HCPs (highly cited patents, cited≥14) of biosensors include more than 10 types of nanomaterials, such as Ag NPs, Au NPs, graphene, CNTs, and polymer nanomaterials, indicating the diversity of nanomaterials and nanotechnologies used in biosensors. The number of HCPs from the USA is as high as 147, which is 3.5 times that of China. The use of nanomaterials in biosensors has been attracting increasing attention from researchers for decades. The sharp increase in patents since 2017 can be attributed to a significant number of new patents from India and China. In terms of the proportion of HCPs in the patent dataset, patented technologies from the US showed higher quality and value compared to those from other countries such as China, South Korea, and India. In the future, research on nanomaterials for biosensors, including metal and carbon-based nanomaterials, may focus on optimising their properties through the development of composite nanomaterials. With the application research of nucleic acid nanomaterials and MOFs, there could potentially be new technological breakthroughs in biosensors.</p>","PeriodicalId":49324,"journal":{"name":"Recent Patents on Nanotechnology","volume":"20 4","pages":"321-338"},"PeriodicalIF":2.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149412335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Nano-based Strategies for Leishmaniasis: Overcoming Drug Resistance, Toxicity, and Delivery Barriers to Transform Clinical Management and Accelerate Translation.","authors":"Megha Garg, Neha Jain, Chirag Jain, Shreya Kaul, Manisha Pandey, Upendra Nagaich","doi":"10.2174/0118722105425521260226104025","DOIUrl":"https://doi.org/10.2174/0118722105425521260226104025","url":null,"abstract":"<p><strong>Introduction: </strong>Leishmaniasis, caused by Leishmania protozoa, is a serious health issue in the endemic areas. Conventional therapies are common but are plagued with drug resistance, toxicity, poor drug availability, and minimal therapeutic outcomes. Recent developments in nanotechnology, along with patent-protected formulations, present new therapeutic prospects by enhancing the solubility, bio-distribution, and targeted delivery of drugs, thus eliminating most of the undesirable effects that traditional treatments have.</p><p><strong>Methods: </strong>The literature search and selection process was conducted in a structured and transparent manner, following a PRISMA-inspired approach. Literature search was conducted across major scientific databases, such as PubMed, Springer, and ScienceDirect, with key terms that included: nanoparticles in leishmaniasis, nanocarriers of leishmaniasis management, and nanoformulations of leishmaniasis. Only original in vivo studies published in the past decade were considered, and reviews, commentaries, and non-efficacy studies were excluded.</p><p><strong>Results: </strong>The primary search produced 1,432 articles, which were narrowed down to 1,150 through elimination of duplicates. A total of 32 studies were found after the screening and application of inclusion/ exclusion criteria. Together, these studies concluded that nano-based systems enhanced the drug solubility, stability, and targeted macrophage delivery, as well as reducing systemic toxicity in comparison to conventional treatment. The majority of formulations had increased parasite clearance in vivo, extended drug circulation, and a lower frequency.</p><p><strong>Discussion: </strong>Research studies demonstrated that different nanoparticle systems, such as liposomes, polymeric, lipid-based, vesicular-based, and metallic nanoparticles, exhibited controlled release, prolonged blood circulation, and mechanisms of avoiding parasite resistance mechanisms. Such encouraging results have not yet translated into practice. Regulatory uncertainties, high cost, and largescale reproducibility are major barriers. However, nano-based strategies coupled with artificial intelligence- driven design have the potential to accelerate clinical translation in endemic regions.</p><p><strong>Conclusion: </strong>Nanotechnology is a new paradigm for the management of leishmaniasis. The development of multidisciplinary collaboration and concentrated research is required to enhance clinical acceptance, cost reduction, and accessibility in endemic areas.</p>","PeriodicalId":49324,"journal":{"name":"Recent Patents on Nanotechnology","volume":"20 4","pages":"370-394"},"PeriodicalIF":2.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149412337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"A Review of Nanoparticle-Mediated Delivery Systems for RNA-Based Therapeutics.","authors":"Bhagavathi Sundaram Sivamaruthi, Periyanaina Kesika, Natarajan Vijay, Natarajan Sisubalan","doi":"10.2174/0118722105390493250915211702","DOIUrl":"10.2174/0118722105390493250915211702","url":null,"abstract":"<p><p>RNA-based therapeutics, such as RNA interference (RNAi) and mRNA therapies, have shown significant potential in treating diseases like cancer, genetic disorders, and respiratory conditions. However, an ongoing challenge is the efficient and targeted delivery of RNA to specific cells while minimizing toxicity and off-target effects. This review examines recent advancements in nanoparticle( s) (NPs) delivery systems, with a focus on RNA-coated liposomes, lipid nanoparticles (LNPs), and size- and surface-modifiable NPs, aiming to overcome the challenges associated with RNA delivery. We also explore the impact of specific patents in this field. The relevant information was collected from the scientific literature. We discussed various NP platforms and their applications, such as RNA-coated liposomes for oral cancer treatment, dry powder formulations of mRNA-loaded LNPs for pulmonary delivery, and LNP-mediated siRNA delivery for respiratory infections. We also explore NP optimization strategies, such as lipid tail modifications for RNA cargos like mRNA and CRISPR/Cas9. These NP-based systems have led to advancements in tumor targeting, intracellular delivery, and RNA release, demonstrating their promise in RNA therapeutics. Relevant patents, such as WO2016044478A1, which details the use of AAV vectors for treating MYOC glaucoma with RNAi targeting MYOC; WO2011158933A1, which describes a siRNA-based pharmaceutical composition for renal fibrosis using liposomes with retinol as a targeting agent; and WO2019173787A1, which specifies bacterial-toxin-derived constructs for oral siRNA delivery, further validate the progress in RNA delivery technologies. Despite these advancements, challenges such as targeting efficiency, endosomal escape, stability, immune system interactions, and scalability still remain. Continued innovation in RNA nanotechnology, drawing on insights from recent patents, is crucial for developing more effective and personalized RNA-based therapies.</p>","PeriodicalId":49324,"journal":{"name":"Recent Patents on Nanotechnology","volume":" ","pages":"303-320"},"PeriodicalIF":2.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145294177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Placing Nanotechnological Innovations and Patent Landscape Under the Lens of Nanoexposomics.","authors":"Rocktotpal Konwarh","doi":"10.2174/0118722105426745260101103923","DOIUrl":"https://doi.org/10.2174/0118722105426745260101103923","url":null,"abstract":"","PeriodicalId":49324,"journal":{"name":"Recent Patents on Nanotechnology","volume":"20 4","pages":"297-302"},"PeriodicalIF":2.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149412339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}